System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Epublish 6 citations

PubMed: 35496279 DOI: 10.3389/fphar.2022.864088

New Advances on Pathophysiology of Diabetes Neuropathy and Pain Management: Potential Role of Melatonin and DPP-4 Inhibitors.

Front Pharmacol 13:864088

Authors: Prabhakar Busa, Yaswanth Kuthati, Niancih Huang, Chih-Shung Wong

Affiliations

  • Department of Anesthesiology, Cathay General Hospital, Taipei, Taiwan.
  • Department of Anesthesiology, Tri-Service General Hospital, Taipei, Taiwan.
  • Grauate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan.

Abstract

Pre-diabetes and diabetes are growing threats to the modern world. Diabetes mellitus (DM) is associated with comorbidities such as hypertension (83.40%), obesity (90.49%), and dyslipidemia (93.43%), creating a substantial burden on patients and society. Reductive and oxidative (Redox) stress level imbalance and inflammation play an important role in DM progression. Various therapeutics have been investigated to treat these neuronal complications. Melatonin and dipeptidyl peptidase IV inhibitors (DPP-4i) are known to possess powerful antioxidant and anti-inflammatory properties and have garnered significant attention in the recent years. In this present review article, we have reviewed the recently published reports on the therapeutic efficiency of melatonin and DPP-4i in the treatment of DM. We summarized the efficacy of melatonin and DPP-4i in DM and associated complications of diabetic neuropathy (DNP) and neuropathic pain. Furthermore, we discussed the mechanisms of action and their efficacy in the alleviation of oxidative stress in DM.

MeSH

Stress, Physiological, Therapeutics, Dipeptidyl-Peptidase Iv Inhibitors, Neuralgia, Melatonin, Diabetes Mellitus, Dipeptidyl Peptidase 4, Pain Management

Cited by